O	0	1	A
O	2	8	double
O	8	9	-
O	9	14	blind
O	15	25	randomized
O	26	31	trial
O	32	34	of
B-intervention	35	40	wound
I-intervention	41	44	and
I-intervention	45	56	intercostal
I-intervention	57	62	space
I-intervention	63	75	infiltration
I-intervention	76	80	with
I-intervention	81	92	ropivacaine
O	93	99	during
O	100	106	breast
O	107	113	cancer
O	114	121	surgery
O	121	122	:
O	123	130	effects
O	131	133	on
B-condition	134	141	chronic
I-condition	142	155	postoperative
I-condition	156	160	pain
O	160	161	.

O	162	165	The
O	166	174	efficacy
O	175	177	of
O	178	183	local
O	184	194	anesthetic
O	195	200	wound
O	201	213	infiltration
O	214	217	for
O	218	221	the
O	222	231	treatment
O	232	234	of
O	235	240	acute
O	241	244	and
O	245	252	chronic
O	253	266	postoperative
O	267	271	pain
O	272	274	is
O	275	288	controversial
O	289	292	and
O	293	298	there
O	299	302	are
O	303	305	no
O	306	314	detailed
O	315	322	studies
O	322	323	.

O	324	327	The
O	328	335	primary
O	336	345	objective
O	346	348	of
O	349	353	this
O	354	359	study
O	360	363	was
O	364	366	to
O	367	375	evaluate
O	376	379	the
O	380	389	influence
O	390	392	of
O	393	404	ropivacaine
O	405	410	wound
O	411	423	infiltration
O	424	426	on
O	427	434	chronic
O	435	439	pain
O	440	445	after
O	446	452	breast
O	453	460	surgery
O	460	461	.

O	462	464	In
O	465	469	this
O	470	481	prospective
O	481	482	,
O	483	493	randomized
O	493	494	,
O	495	501	double
O	501	502	-
O	502	507	blind
O	507	508	,
O	509	517	parallel
O	517	518	-
O	518	523	group
O	523	524	,
O	525	532	placebo
O	532	533	-
O	533	543	controlled
O	544	549	study
O	549	550	,
B-total-participants	551	554	236
O	555	563	patients
O	564	573	scheduled
O	574	577	for
O	578	584	breast
O	585	591	cancer
O	592	599	surgery
O	600	604	were
O	605	615	randomized
O	616	617	(
O	617	618	1
O	618	619	:
O	619	620	1
O	620	621	)
O	622	624	to
O	625	632	receive
O	633	644	ropivacaine
O	645	647	or
B-control	648	655	placebo
O	656	668	infiltration
O	669	671	of
O	672	675	the
O	676	681	wound
O	681	682	,
O	683	686	the
O	687	693	second
O	694	697	and
O	698	703	third
O	704	715	intercostal
O	716	722	spaces
O	723	726	and
O	727	730	the
O	731	738	humeral
O	739	748	insertion
O	749	751	of
O	752	757	major
O	758	768	pectoralis
O	768	769	.

B-outcome-Measure	770	775	Acute
I-outcome-Measure	776	780	pain
O	780	781	,
B-outcome-Measure	782	791	analgesic
I-outcome-Measure	792	803	consumption
O	803	804	,
B-outcome-Measure	805	811	nausea
I-outcome-Measure	812	815	and
I-outcome-Measure	816	824	vomiting
O	825	829	were
O	830	838	assessed
O	839	844	every
O	845	847	30
O	848	851	min
O	852	855	for
O	856	857	2
O	858	859	h
O	860	862	in
O	863	866	the
O	867	881	postanesthesia
O	882	886	care
O	887	891	unit
O	892	895	and
O	896	901	every
O	902	903	6
O	904	905	h
O	906	909	for
O	910	912	48
O	913	914	h
O	914	915	.

O	916	923	Chronic
O	924	928	pain
O	929	932	was
O	933	942	evaluated
O	943	944	3
O	945	951	months
O	951	952	,
O	953	954	6
O	955	961	months
O	961	962	,
O	963	966	and
O	967	968	1
O	969	971	yr
O	972	977	after
O	978	985	surgery
O	986	988	by
O	989	992	the
O	993	998	brief
O	999	1003	pain
O	1004	1013	inventory
O	1013	1014	,
O	1015	1023	hospital
O	1024	1031	anxiety
O	1032	1035	and
O	1036	1046	depression
O	1046	1047	,
O	1048	1051	and
O	1052	1063	neuropathic
O	1064	1068	pain
O	1069	1083	questionnaires
O	1083	1084	.

O	1085	1096	Ropivacaine
O	1097	1102	wound
O	1103	1115	infiltration
O	1116	1129	significantly
O	1130	1139	decreased
O	1140	1149	immediate
B-outcome	1150	1163	postoperative
I-outcome	1164	1168	pain
O	1169	1172	for
O	1173	1176	the
O	1177	1182	first
O	1183	1185	90
O	1186	1189	min
O	1189	1190	,
O	1191	1194	but
O	1195	1198	did
O	1199	1202	not
O	1203	1211	decrease
O	1212	1219	chronic
O	1220	1224	pain
O	1225	1227	at
O	1228	1229	3
O	1230	1236	months
O	1237	1238	(
O	1238	1245	primary
O	1246	1254	endpoint
O	1254	1255	)
O	1255	1256	,
O	1257	1259	or
O	1260	1262	at
O	1263	1264	6
O	1265	1268	and
O	1269	1271	12
O	1272	1278	months
O	1279	1294	postoperatively
O	1294	1295	.

O	1296	1298	At
O	1299	1300	3
O	1301	1307	months
O	1307	1308	,
O	1309	1312	the
B-outcome	1313	1322	incidence
I-outcome	1323	1325	of
I-outcome	1326	1333	chronic
I-outcome	1334	1338	pain
O	1339	1342	was
B-iv-bin-percent	1343	1345	33
I-iv-bin-percent	1345	1346	%
O	1347	1350	and
B-cv-bin-percent	1351	1353	27
I-cv-bin-percent	1353	1354	%
O	1355	1356	(
O	1356	1357	P
O	1358	1359	=
O	1360	1361	0
O	1361	1362	.
O	1362	1364	37
O	1364	1365	)
O	1366	1368	in
O	1369	1372	the
O	1373	1384	ropivacaine
O	1385	1388	and
O	1389	1396	placebo
O	1397	1403	groups
O	1403	1404	,
O	1405	1417	respectively
O	1417	1418	.

O	1419	1425	During
O	1426	1432	follow
O	1432	1433	-
O	1433	1435	up
O	1435	1436	,
B-outcome	1437	1442	brief
I-outcome	1443	1447	pain
I-outcome	1448	1457	inventory
O	1457	1458	,
B-outcome	1459	1470	neuropathic
I-outcome	1471	1475	pain
O	1475	1476	,
O	1477	1480	and
B-outcome	1481	1488	anxiety
O	1489	1498	increased
O	1499	1503	over
O	1504	1508	time
O	1509	1511	in
O	1512	1516	both
O	1517	1523	groups
O	1524	1525	(
O	1525	1526	P
O	1527	1528	<
O	1529	1530	0
O	1530	1531	.
O	1531	1534	001
O	1534	1535	)
O	1536	1541	while
O	1542	1552	depression
O	1553	1561	remained
O	1562	1568	stable
O	1568	1569	.

O	1570	1572	No
B-outcome	1573	1586	complications
O	1587	1595	occurred
O	1595	1596	.

O	1597	1601	This
O	1602	1613	multicenter
O	1613	1614	,
O	1615	1626	prospective
O	1627	1632	study
O	1633	1638	shows
O	1639	1643	that
O	1644	1655	ropivacaine
O	1656	1661	wound
O	1662	1674	infiltration
O	1675	1680	after
O	1681	1687	breast
O	1688	1694	cancer
O	1695	1702	surgery
O	1703	1712	decreased
O	1713	1722	immediate
O	1723	1736	postoperative
O	1737	1741	pain
O	1742	1745	but
O	1746	1749	did
O	1750	1753	not
O	1754	1762	decrease
O	1763	1770	chronic
O	1771	1775	pain
O	1776	1778	at
O	1779	1780	3
O	1780	1781	,
O	1782	1783	6
O	1783	1784	,
O	1785	1788	and
O	1789	1791	12
O	1792	1798	months
O	1799	1814	postoperatively
O	1814	1815	.
